JPRN-jRCT2022210028招募中2 期
An Exploratory Study of FHM-001 in Patients with Depression/Multicenter, parallel-group study
Furukawa Toshiaki0 个研究点目标入组 143 人开始时间: 2021年8月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 143
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 < 65age old（—）
- 性别
- All
入选标准
- •(1)Japanese patients aged 18 to less than 65 years who provided appropriate written informed consent
- •(2)Ongoing episodes with primary diagnosis of non-psychotic depression (DSM -5)
- •(3)A total score of > 10 on the PHQ -9 scale and a total score of > 17 on the HAM-D (17 items) scale by the central assessment.
- •(4)Subject must have a Clinical Global Impression of Change (CGI-I) score of > 3 (mild improvement) and no response or partial response, in the opinion of the investigator, to any single standard of care antidepressant [Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin and Noradrenaline Reuptake Inhibitors (SNRI), Noradrenergic and Specific Serotonergic Antidepressants (NaSSA)] after at least 4 weeks of stable treatment.
- •(5)Patients who have been taking one of the antidepressants used as standard of care drugs (SSRIs, SNRIs, NaSSAs) at a fixed dosage and administration for 4 weeks or longer and who are judged by the investigator/subinvestigator to have no problem with tolerability and to be able to continue the treatment without changing the dosage and administration
排除标准
- •(1)Patients with previous or current schizophrenia or other psychotic disorders, or bipolar disorder or other related disorders, based on the diagnostic criteria in the DSM-5
- •(2)Patients with any of the following disorders based on the diagnostic criteria in the DSM-5: Delirium, dementia, substance-related disorder, borderline personality disorder, eating disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, intellectual disability, and autistic spectrum disorder
- •(3)Patients with a significant risk of suicide who have had suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS) type 4 or 5 within the past 3 months or committed suicidal behavior within 1 year prior to the start of the screening period
- •(4)Patients under hospitalization, or patients scheduled to be hospitalized for the treatment of a physical disorder or depression during the study period
- •(5)Patients who have received systematic individual psychotherapy (cognitive behavioral therapy [CBT], interpersonal therapy, dynamic psychotherapy, problem-solving therapy, psychoanalytic therapy, etc.) for the episode concerned
- •(6)Patients who have received electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS) for the episode concerned
- •(7)Patients who cannot use antidepressants (SSRI, SNRI, or NaSSA) specified as the standard treatments
- •(8)Patients with a history of diagnosis or treatment of malignancy within 5 years before the start of the screening period, or patients with current malignancy
- •(9)Female patients who are pregnant, breastfeeding, or may be pregnant
- •(10)Male patients and female patients of childbearing potential who do not agree to practice contraception during the study period
- •(11)Patients who have participated in a clinical study of a CBT application and used the CBT application
研究者
相似试验
招募中
1 期
HM-001-CT1 StudyJPRN-jRCT2051230033Kawashima Atsunari48
进行中（未招募）
1 期
An Early Phase Study of DCR-PH1 in Patients with an Inherited Disorder Resulting in Overproduction of OxalatePrimary Hyperoxaluria Type 1MedDRA version: 18.1Level: PTClassification code 10020703Term: HyperoxaluriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-003142-51-NLDicerna Pharmaceuticals, Inc.4
已完成
不适用
A Phase 1 Study of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)Autosomal recessive disorderPH1NL-OMON44062Dicerna Pharmaceuticals, lnc7
进行中（未招募）
1 期
An Early Phase Study of DCR-PH1 in Patients with an Inherited Disorder Resulting in Overproduction of OxalatePrimary Hyperoxaluria Type 1MedDRA version: 18.0 Level: PT Classification code 10020703 Term: Hyperoxaluria System Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-003142-51-GBDicerna Pharmaceuticals, Inc.4
进行中（未招募）
1 期
A Phase I/Ib study of DFF332 as a single agent and in combination with Everolimus or Immuno-oncology therapies in patients with advanced/relapsed ccRCC and other malignancies with HIF2alpha stabilizing mutations.Advanced, relapsed Clear Cell Renal Cell CarcinomaMedDRA version: 21.0Level: LLTClassification code 10038396Term: Renal carcinoma recurrentSystem Organ Class: 100000004864EUCTR2020-004383-25-ESovartis Farmacéutica, S.A.187